Cadila Healthcare Limited

Shriprakash Dhar Dwivedi

Ashok Prasad

Dhimant Jasubhai Patel

Brij Khera

Jayprakash Ajitsingh Parihar

Piyush Rajendra Sharma

Mukul Hariprasad Sharma

Kumar Kamlesh Singh

Alpesh Pravinchandra Shah

Ramesh Chandra Singh

Kuldeep Natwarlal Jain

Daya Ram Pal

Mahesh Laljibhai Rupapara

Nikhil Amar Singh

Vikas Patel

Jigar Mukundbhai Raval

Jitendra Maganbhai Gajera

Pranav Jitendra Gangwar

Vishwadeepak Rama Pati Tripathi

Chetan Jayantibhai Vasava

Rajendra Gokalbhai Chavda

Amol Kashinath Patil

Jagdish Maganlal Patel

Alpeshkumar Pravinchandra Shah

Samir Rameshbhai Gajjar

Ganpant Dan Shimbu Charan

Jaiprakash Ajitsingh Parihar

Rushikesh Udaykumar Roy

Kishor Maneklal Vinchhi

Rajiv Kumar

Sunil Tribhovandas Patel

Alpeshkumar Parvin Chandra Shah

Sachin Ashokrao Patil

Jigar Mukundhai Raval

Vishwadeepak Rama Patil Tripathi

The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.

Process for preparation of pyrroles having hypolipidemic hypocholesteremic activities

The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof. The invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of linagliptin and use of the composition for treatment of diabetes especially type-I or type-II, prediabetes or reduction of glucose tolerance.

Amorphous form of linagliptin and process for preparation thereof

Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed.

Polymorphic forms of ivabradine hydrochloride

The present invention relates to stable crystalline Form I of lorcaserin hydrochloride of Formula (IA) and processes for its preparation. The invention also relates to processes for the preparation of lorcaserin and pharmaceutically acceptable salts, solvates and hydrates thereof.

Processes for the preparation of lorcaserin

The field of the invention relates to a process for the preparation of amorphous imatinib mesylate. In particular, the invention relates to a process for the preparation of stable amorphous imatinib mesylate. More particularly, the invention relates to pharmaceutical compositions that includes the stable amorphous imatinib messylate together along with its excipients.

Process for the preparation of amorphous imatinib mesylate

A stable amorphous form of dasatinib of Formula (I) wherein amorphous dasatinib after exposure to a relative humidity of 75% at 40 &#xb0; C. or 60% at 25 &#xb0; C. for a period of at least three months doesn't change to crystalline form and a process for the preparation of the amorphous form of dasatinib of Formula (I). 

Process for preparation of amorphous form of dasatinib

The present invention provides crystalline form of intermediates of Formula 2A,  The present invention also provides process for the preparation of dabigatran etexilate mesylate; polymorph of intermediates thereof; particularly processes for the preparation of crystalline form of intermediates. The present invention also relates to the use of crystalline intermediates for the preparation of dabigatran etexilate mesylate.

Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof

The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.

Method of preparation of pitavastatin and pharmaceutical acceptable salts thereof

The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions.

Pitavastatin calcium and process for its preparation

The invention relates to improved process for the preparation of fesoterodine and its pharmaceutically acceptable salt, specifically fesoterodine fumarate of formula (1). The invention relates to solid state forms of a novel salt of fesoterodine and process for the preparation thereof. The invention also relates to highly pure fesoterodine fumarate substantially free of impurity X at RRT 1.37. The invention also provides solid particles of pure fesoterodine fumarate wherein 90 volume-percent of the particles (D90) have a size of higher than 200 microns.

Processes for the preparation of fesoterodine

The present invention discloses one pot process for enantioselective synthesis of single enantiomers of substituted sulphoxides 2-(2-pyridinylmethylsulphinyl)-1H-benzimidazoles or said compounds in an enantiomerically enriched form.

One-pot process for the preparation of benzimidazole derivatives

The present invention discloses polymorphic forms of O-desmethyl-venlafaxine succinate and processes for the preparation thereof.

Polymorphic forms of O-desmethyl-venlafaxine succinate

Growing community of inventors

Gujarat, India

Shriprakash Dhar Dwivedi